Supplementary Figure 6: TBK1 and c-Rel inhibition overcome β3-mediated erlotinib resistance.
From: An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
(a) Immunoblots showing TBK1 and c-Rel knockdown efficiency in cells used in this study. (b) Phase contrast images of self-renewal tumour spheres of FGβ3 expressing non-silencing shCTRL or TBK1 specific shRNA. Scale bar, 100 μm. (c) Effect of TBK1 and c-Rel knockdown measured by CellTiterGLO cell viability assay for FG cells. Cells were grown in 3D. The bar graph represents mean for 2 wells per group. Data are representative experiment of 2 independent experiments. (d) Confocal microscopy images of c-Rel (red) and DNA (TOPRO-3, blue) in FGβ3 cells treated with vehicle, or bortezomib 20 nM. Scale bar, 50 μm. (e) Confocal microscopy images of cleaved caspase 3 (red) and DNA (TOPRO-3, blue) in FGβ3 tumour biopsies from xenografts tumours used in Fig. 7g treated with vehicle, erlotinib, bortezomib or bortezomib and erlotinib in combo. Scale bar, 100 μm. Uncropped western-blots are provided in Supplementary Figure 7. Original data for c are provided in the Statistical source data (Supplementary Table 3).
